Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pitavastatin + ceftobiprole
- Development stage
- Phase 1
- Lead developer
- Basilea Pharmaceutica
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Pitavastatin + ceftobiprole is a combination of two pharmaceutical agents with distinct mechanisms and indications. Pitavastatin is an oral small molecule statin used to lower high cholesterol and triglyceride levels in the blood while increasing HDL cholesterol. It works by inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis[1]. Ceftobiprole is a fifth-generation injectable cephalosporin antibiotic (marketed as Zevtera) indicated for the treatment of Staphylococcus aureus bloodstream infections (bacteremia), acute bacterial skin and skin structure infections (ABSSSI), and community-acquired bacterial pneumonia (CABP). Ceftobiprole acts by binding to penicillin-binding proteins (PBPs), including PBP2a in MRSA strains, thereby inhibiting cell wall synthesis and causing bacterial cell death[2][3][4][5][6].
- Brand names
- Livazo
- Other names
- pitavastatin calciumceftobiprole medocaril
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)NR4A2 (Nuclear receptor subfamily 4 group A member 2)PBP2B (Penicillin-binding protein 2B)PBP2x (Penicillin-binding protein 2x)PBP5 (D-alanyl-D-alanine carboxypeptidase DacA)RXRA (Retinoid X receptor alpha)
Beyond the preview
Go deeper on pitavastatin + ceftobiprole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pitavastatin + ceftobiprole.